Wanda Haeck
Leuven, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Journal: Molecular cancer therapeutics
Published: November 04, 2022
Molecular Dissection of FUS Points at Synergistic Effect of Low-Complexity Domains in Toxicity.
Journal: Cell reports
Published: September 13, 2017
Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Journal: Neurobiology of disease
Published: July 13, 2017
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.
Journal: Brain : a journal of neurology
Published: June 13, 2017
Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors.
Journal: Organic & biomolecular chemistry
Published: January 30, 2016
Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.
Journal: ACS chemical neuroscience
Published: November 25, 2015
Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors.
Journal: Chemical communications (Cambridge, England)
Published: May 22, 2015
Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis.
Journal: Brain : a journal of neurology
Published: February 05, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026